To keep you up-to-date in the clinical management on CML the iCMLf is pleased to present to you monthly updates from key CML publications. Stories deliver the latest research, findings, thoughts and opinions in the fast moving world of medical research and clinical trials ensuring you know 'what's hot'.
Stories are based on articles published in international peer-reviewed journals, or conference sessions and written by highly experienced and knowledgeable writers.
Articles contain full references, so you can easily find background information and further reading if desired.
This independent educational resource is provided as a special service by the iCMLf in partnership with Springer Healthcare IME and is supported by a grant from Novartis Oncology.
Research suggests that the relationship between a fluctuating response to imatinib and the likelihood of developing resistance to the tyrosine kinase inhibitor depends on the depth of molecular response achieved by the CML patient.(Source: Br J Haematol, February 2017; advance online publication)
(Source: Clin Lymphoma Myeloma Leuk, February 2017; advance online publication)
Click here to see a list of recent clinical and scientific publications from peer-reviewed journals